MRM Proteomics and Biodesix Partner to Develop Precision Lung Cancer Diagnostics
MRM Proteomics Inc. and Biodesix® have inked a partnership to create novel assays to answer clinical questions within the lung cancer continuum of care.
×
254 Results
MRM Proteomics Inc. and Biodesix® have inked a partnership to create novel assays to answer clinical questions within the lung cancer continuum of care.
Biodesix, Inc. this week highlighted findings from multiple studies demonstrating the significance and clinical utility of its VeriStrat® blood-based proteomic test.
Biodesix highlighted their development and commercialization of companion diagnostics for directing the treatment of non-small cell lung cancer at the 2019 Clinical Biomarkers & World CDx Conference.
Biodesix will acquire Oncimmune’s laboratory and incidental pulmonary nodule malignancy test in the U.S.
Biodesix will release new data demonstrating the potential diagnostic utility of a blood-based test for patients with resistance to osimertinib, and on the precision of liquid biopsy
Biodesix appointed Robert W. Georgantas III, Ph.D., as the company’s Senior Vice President (SVP) of Research and Translational Science.
Biodesix has entered into an agreement with Thermo Fisher Scientific.
Biodesix, Inc. the leader in lung cancer diagnostics, today announced the appointment of internationally recognized lung cancer expert, James Jett, M.D., as Chief Medical Officer.
Biodesix presented new data showing that the VeriStrat® test is predictive of outcomes for patients with non-small cell lung cancer treated with immune checkpoint inhibitors
Biodesix announced that it is collaborating with immune-oncology firm Immodulon Therapeutics to identify proteomic markers linked to pancreatic cancer.
Biodesix announces the appointment of Charles Watts, M.D. to the company’s board of directors.
Biodesix, Inc., today announced it has been issued U.S. Patent Number 10,422,729, which covers the Biodesix Collection Device (BCD).
Biodesix, Inc. has been named Company of the Year by the Colorado BioScience Association. The company was honored at the 16th Annual CBSA Awards Dinner.
AVEO Oncology and Biodesix Announce Initiation of the CyFi-2 Study, a Phase 2 Randomized Study of Ficlatuzumab in Combination with High-Dose Cytarabine vs. High-Dose Cytarabine Alone in Patients with Relapsed and Refractory AML.
Biodesix, Inc., today announced that it has completed acquisition of Oncimmune’s laboratory and incidental pulmonary nodule (IPN) malignancy test in the United States.
Biodesix, Inc., the leader in lung cancer diagnostic solutions, today announced that current Chief Operating Officer Scott Hutton will become Chief Executive Officer on January 1, 2020.
Biodesix, Inc. today announced that Tri-Star Health in Nashville, TN is the first hospital system in the U.S. to adopt the recently launched Nodify XL2™ proteomic nodule classifier for incidental lung nodule management.